Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC lifted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 16.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 143,436 shares of the company's stock after buying an additional 19,991 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.30% of Amphastar Pharmaceuticals worth $5,326,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Amphastar Pharmaceuticals by 9.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after purchasing an additional 105,288 shares in the last quarter. Boston Trust Walden Corp raised its stake in Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Northern Trust Corp raised its stake in Amphastar Pharmaceuticals by 5.1% during the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company's stock valued at $22,767,000 after purchasing an additional 29,808 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in Amphastar Pharmaceuticals by 7.1% during the fourth quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock valued at $22,601,000 after purchasing an additional 40,212 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AMPH shares. Wells Fargo & Company decreased their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Trading Up 0.9%

AMPH stock traded up $0.24 during mid-day trading on Friday, reaching $25.88. 460,917 shares of the stock traded hands, compared to its average volume of 484,740. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The stock has a market capitalization of $1.23 billion, a PE ratio of 8.63, a PEG ratio of 2.19 and a beta of 0.78. The business has a 50-day moving average price of $24.92 and a two-hundred day moving average price of $32.15.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 5,231 shares of company stock worth $142,752. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.